| Cat. No. |
Product Name |
Information |
| PC-38176 |
NV-5138
|
NV-5138 (NV5138) is the first selective, orally bioavailable brain mTORC1 activator, binds to Sestrin2 (Kd=1.5 uM) and activates mTORC1 both in vitro and in vivo. |
| PC-36112 |
MTI-31
|
MTI-31 (LXI-15029, mTOR inhibitor-31) is a novel potent, selective mTORC1/mTORC2 inhibitor with Kd of 0.2 nM (mTOR), displays >5,000-fold selectivity over PIK3CA, PIK3CB and PIK3G. |
| PC-60555 |
NV-128
|
NV-128 (LY-303511) is a novel isoflavone derivative that inhibits mTOR and promotes caspase-independent cell death. |
| PC-60554 |
ME-344
|
ME-344 is a novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM. |
| PC-60418 |
RapaLink-1
|
RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors. |
| PC-45649 |
Seco Rapamycin sodium salt
|
Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.. |
| PC-42608 |
PP 242
|
Torkinib (PP242) is a potent, specific active-site inhibitor of mTOR with IC50 of 30 and 58 nM for mTORC1 and mTORC2, respectively. |
